{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-341230","form_type":"8-K","ticker":"SION","cik":"0002036042","company_name":"Sionna Therapeutics, Inc.","filed_at":"2026-08-10T11:15:06+00:00","discovered_at":"2026-08-10T11:20:06.264637+00:00","generated_at":"2026-08-10T11:20:20.394943+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Sionna's SION-719 Phase 2a misses sweat chloride endpoint; program halted as add-on","bullets":["SION-719 Phase 2a missed key endpoint: -1.0 mmol/L placebo-adjusted sweat chloride change (p=0.7); not advancing as add-on to SOC.","Phase 1 of SION-451 dual combos met safety/PK goals; SION-451 + SION-2222 preferred; evaluating next steps.","Q2 cash $268.3M; plans to preserve capital while assessing SION-451 program.","SION-719 was well tolerated; no serious AEs; potential confounders (variability, Trikafta exposure) under review."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-341230","json":"https://secwatch.observer/filing/0001193125-26-341230.json","markdown":"https://secwatch.observer/filing/0001193125-26-341230.md","text":"https://secwatch.observer/filing/0001193125-26-341230.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2036042/000119312526341230/0001193125-26-341230-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2036042/000119312526341230/d135438d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-10T11:20:20.394943+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}